StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the stock.
Separately, Benchmark reiterated a hold rating on shares of VolitionRx in a research note on Friday, August 16th.
View Our Latest Stock Report on VNRX
VolitionRx Stock Up 16.2 %
VolitionRx (NYSE:VNRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. Equities research analysts expect that VolitionRx will post -0.31 earnings per share for the current year.
Insider Activity at VolitionRx
In other news, Director Guy Archibald Innes acquired 150,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was acquired at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the completion of the transaction, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 12.80% of the stock is currently owned by corporate insiders.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
- Five stocks we like better than VolitionRx
- Investing In Automotive Stocks
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- How is Compound Interest Calculated?
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- The Significance of Brokerage Rankings in Stock Selection
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.